Recently, treatment with Imatinib and GNF-5 has been reported to suppress the expression of Skp2 (Chen et al., 2009), and induce G0/G1 cell cycle arrest, increase p27 and p21 protein levels, inhibiting cell growth in hepatocellular carcinoma (HCC) (Zhang et al., 2020), implying that these two drugs could be used as a potential Skp2-inhibiting compounds indirectly. Here, SKP2 is linked to hepatocellular carcinoma.